Act Two Investors LLC boosted its stake in Stryker Corporation (NYSE:SYK – Free Report) by 13.8% in the third quarter, HoldingsChannel reports. The firm owned 57,147 shares of the medical technology company’s stock after acquiring an additional 6,930 shares during the period. Stryker makes up approximately 3.0% of Act Two Investors LLC’s holdings, making the stock its 12th largest holding. Act Two Investors LLC’s holdings in Stryker were worth $15,738,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in SYK. Danske Bank A S boosted its position in Stryker by 4.5% in the third quarter. Danske Bank A S now owns 218,478 shares of the medical technology company’s stock worth $60,167,000 after purchasing an additional 9,421 shares during the last quarter. Condor Capital Management grew its stake in shares of Stryker by 1.9% during the 3rd quarter. Condor Capital Management now owns 11,002 shares of the medical technology company’s stock valued at $3,030,000 after purchasing an additional 203 shares during the period. AlpenGlobal Capital LLC increased its position in shares of Stryker by 1.0% during the 3rd quarter. AlpenGlobal Capital LLC now owns 6,217 shares of the medical technology company’s stock valued at $1,712,000 after purchasing an additional 62 shares during the last quarter. Vista Capital Partners Inc. purchased a new stake in shares of Stryker during the 3rd quarter valued at about $5,344,000. Finally, Moors & Cabot Inc. boosted its holdings in shares of Stryker by 28.3% in the third quarter. Moors & Cabot Inc. now owns 11,524 shares of the medical technology company’s stock worth $3,174,000 after buying an additional 2,539 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Stryker
In other news, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 901,267 shares of company stock valued at $297,123,701 over the last three months. Corporate insiders own 4.60% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Stock Analysis on SYK
Stryker Stock Performance
Shares of NYSE:SYK traded down $3.34 during mid-day trading on Friday, reaching $309.05. 3,251,740 shares of the company traded hands, compared to its average volume of 3,235,306. The company’s 50 day moving average price is $292.30 and its 200-day moving average price is $322.60. The firm has a market cap of $117.65 billion, a PE ratio of 32.91, a PEG ratio of 2.14 and a beta of 0.78. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30.
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The firm had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. Stryker’s revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.19 EPS. On average, equities analysts expect that Stryker Corporation will post 14.85 EPS for the current fiscal year.
Stryker Company Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Further Reading
- Five stocks we like better than Stryker
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
